Chronic Kidney DiseasesNCT07153432
Chronic Kidney Disease Screening
An observational study of Chronic Kidney Diseases, run by Institute for Clinical and Experimental Medicine at 1 site in Czechia.
Trial summary
The goal of this observational study is to assess epidemiology of chronic kidney disease in patients followed at a tertiary care center. The main question it aims to answer is: What is the proportion of patients with chronic kidney disease overall and how many are previously undiagnosed. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Chronic Kidney Diseases
- How many people
- 3,000 participants
- Where
- 1 siteCzechia
- Study dates
- 24 Feb 2025to 31 Jan 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult patients followed at the Institute for Clinical and Experimental Medicine
Who may be able to join
- age > 50 or age >18 + one of these conditions (history of diabetes, arterial hypertension, ischemic heart disease, stroke, perpheral artery disease, atrial fibrillation, heart failure)
- agree to participate
- followed at the Institute for Clinical and Experimental Medicine
Who cannot join
- unwilling to participate
- kidney transplant recipient/previous kidney transplantation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Vojtech Petr, MD contact
Czechia1 site, 1 recruiting
- Recruiting
Institute for Clinical and Experimental Medicine
Prague, 14021
Ivan Zahradka, MD, +420261364110, zahi@ikem.cz
Vojtech Petr, MD, petv@ikem.cz
About this study
Official title: Chronic Kidney Disease Screening in Patients Followed at a Tertiary Care Center
The goal of this observational study is to assess epidemiology of chronic kidney disease in patients followed at a tertiary care center. The main question it aims to answer is: What is the proportion of patients with chronic kidney disease overall and how many are previously undiagnosed.
- Conditions
- Chronic Kidney Diseases
- Keywords
- chronic kidney disease, screening, epidemiology
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Case group | Not described | |
| Control group | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients with chronic kidney disease
Chronic kidney disease diagnosed with either decreased estimated glomerular filtration rate and/or increased albumin excretion in urine
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Sep 2025
- Study start24 Feb 2025
- Primary completion19 Oct 2025 (estimated)
- Study completion31 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Kidney DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institute for Clinical and Experimental Medicine
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Prof. Ondřej Viklický, M.D., Ph.D., Institute for Clinical and Experimental Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07153432
- Sponsor's protocol ID
- 23575/25
- Status last verified
- Aug 2025
- First submitted
- 6 Aug 2025
- Last updated
- 4 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Zahradka I, Petr V, Tichanek F, Chroma A, Neskudla T, Kahle M, Bem R, Trunecka P, Adamkova V, Hruba P, Hlavac I, Viklicky O. Prevalence, risk factors and renoprotective treatment of chronic kidney disease among internal medicine outpatients at a Central European tertiary care centre: a cross-sectional study. BMJ Open. 2026 Oct 6;16(10):e121190. doi: 10.1136/bmjopen-2026-121190.
PubMed 42838586
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chronic Kidney Disease Screening in Patients Followed at a Tertiary Care Center
- ClinicalTrials.gov ID
- NCT07153432
- Acronym / sponsor ID
- 23575/25
- Conditions
- Chronic Kidney Diseases
- Keywords
- chronic kidney disease, screening, epidemiology
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- Institute for Clinical and Experimental MedicineOther government
- Study start
- 24 Feb 2025 (actual)
- Primary completion
- 19 Oct 2025 (estimated)
- Study completion
- 31 Jan 2026 (estimated)
- First posted
- 4 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to assess epidemiology of chronic kidney disease in patients followed at a tertiary care center. The main question it aims to answer is: What is the proportion of patients with chronic kidney disease overall and how many are previously undiagnosed.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Case group | – | – |
| Control group | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients followed at the Institute for Clinical and Experimental Medicine
Key inclusion criteria (3 listed)
- age > 50 or age >18 + one of these conditions (history of diabetes, arterial hypertension, ischemic heart disease, stroke, perpheral artery disease, atrial fibrillation, heart failure)
- agree to participate
- followed at the Institute for Clinical and Experimental Medicine
Key exclusion criteria (2 listed)
- unwilling to participate
- kidney transplant recipient/previous kidney transplantation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Proportion of patients with chronic kidney disease
Time frame: Baseline
Chronic kidney disease diagnosed with either decreased estimated glomerular filtration rate and/or increased albumin excretion in urine
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2025.
- Derived from this study: PubMed 42838586Zahradka I, Petr V, Tichanek F, Chroma A, Neskudla T, Kahle M, Bem R, Trunecka P, Adamkova V, Hruba P, Hlavac I, Viklicky O. Prevalence, risk factors and renoprotective treatment of chronic kidney disease among internal medicine outpatients at a Central European tertiary care centre: a cross-sectional study. BMJ Open. 2026 Oct 6;16(10):e121190. doi: 10.1136/bmjopen-2026-121190.
Related trials for Chronic Kidney Diseases
Not yet recruiting
Negative Pressure Wound Therapy Devices in Total Knee Arthroplasty
Wound Surgical, Diabetes
RecruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Recruiting
Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes
Type 2 Diabetes Mellitus, Acute Kidney Injury
Recruiting
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
End Stage Renal Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Vojtech Petr, MD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Kidney Diseases, run by Institute for Clinical and Experimental Medicine at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ivan Zahradka, MD (+420261364110, zahi@ikem.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients with chronic kidney disease (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07153432, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2025.